Imatinib: Novel treatment of immune-mediated kidney injury

Eric Wallace, Leslie Gewin

Research output: Contribution to journalShort surveypeer-review

18 Scopus citations


The treatments for many autoimmune diseases are limited in efficacy, and long-term use is associated with severe adverse events. The tyrosine kinase inhibitors have proven to be well tolerated for long treatment periods, with minimal adverse events, in the oncology population. These agents have recently been used to treat autoimmune diseases. We review the potential mechanisms whereby tyrosine kinase inhibitors may modulate the immune response and inhibit fibrogenesis and discuss the current evidence for their use in the treatment of autoimmune diseases of the kidney.

Original languageEnglish
Pages (from-to)694-701
Number of pages8
JournalJournal of the American Society of Nephrology
Issue number5
StatePublished - Apr 30 2013


Dive into the research topics of 'Imatinib: Novel treatment of immune-mediated kidney injury'. Together they form a unique fingerprint.

Cite this